Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows: Abdominal, Small Organ, Transrectal, Transvaginal, Peripheral Vascular.
CLI 4900 6.5MHz Trans-vaginal (endocavity) probe: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows: Transvaginal.
CLI 5000 6.5MHz Trans-rectal (endocavity) probe: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows: Transrectal.
CLI 6000 12.5MHz Peripheral Vascular probe: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows: Small Organ, Peripheral Vascular.
CLI 7900 3.5MHz General Abdominal probe: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows: Abdominal.

Device Description

Not Found

AI/ML Overview

The provided document is a 510(k) premarket notification letter from the FDA to SonoVision Corporation regarding their SONADA Ultrasound System. It primarily outlines the substantial equivalence determination for the device and its transducers.

Crucially, this document does not contain information about acceptance criteria or a study proving the device meets acceptance criteria.

The FDA letter grants clearance based on the device being substantially equivalent to legally marketed predicate devices, meaning it has the same intended use and technological characteristics as an already cleared device, or if there are differences, those differences do not raise new questions of safety or effectiveness. The information provided is primarily about the categorization and clearance of the device for marketing, and not about the detailed performance studies you're asking for.

Therefore, I cannot extract the following information from the provided text:

A table of acceptance criteria and the reported device performance: This information is not present. The document focuses on regulatory clearance, not performance metrics.
Sample size used for the test set and the data provenance: This information is not present. There's no mention of a specific test set or data sources for performance evaluation.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts: This information is not present.
Adjudication method for the test set: This information is not present.
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, and the effect size: This information is not present.
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: This information is not present. The device is a diagnostic ultrasound system, implying human operation.
The type of ground truth used: This information is not present.
The sample size for the training set: This information is not present.
How the ground truth for the training set was established: This information is not present.

The document mainly lists the transducers approved and their intended clinical applications (e.g., Abdominal, Transvaginal, Transrectal, Peripheral Vascular, Small Organ) with "P" indicating "previously cleared by FDA" for those applications. This implies that the substantial equivalence determination relied on prior clearances for similar devices performing these functions, rather than new, explicit performance studies detailed within this letter. The "postclearance special report" mentioned relates to acoustic output measurements based on production units, which is a post-market requirement, not a pre-market performance study.

Summary

{0}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/0/Picture/14 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is a circular seal with the department's name around the perimeter. Inside the circle is a stylized image of an eagle with three lines representing its wings.

Public Health Service

APR 1 4 2000

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Paul Schneider, Ph.D. Requlatory Affairs Consultant SonoVision Corporation 377 Route 17 South Suite 204 Hasbrouck Heights, NJ 07604

Re : K993092 SONADA Ultrasound System Regulatory Class: II/21 CFR 892.1560/21 CFR 892.1550 Product Code: 90 IYO/90 IYN Dated: March 10, 2000 Received: March 13, 2000

Dear Dr. Schneider:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

This determination of substantial equivalence applies to the following transducers intended for use with the SONADA Ultrasound System, as described in your premarket notification:

Probe Model Numbers

CLI 4900 6.5MHz Trans-vaginal (endocavity) probe CLI 5000 6.5MHZ Trans-rectal (endocavity) probe CLI 6000 12.5MHz Peripheral Vascular probe CLI 7900 3.5MHz General Abdominal probe

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. ನ್ನ substantially equivalent determination assumes compliance with the Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic QS inspections, the FDA will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification does not affect any obligation you may have under sections 531 and 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{1}------------------------------------------------

Page 2 - Paul Schneider, Ph.D.

This determination of substantial equivalence is granted on the condition that prior to shipping the first device, you submit a postclearance special report. This report should contain complete information, including acoustic output measurements based on production line devices, requested in Appendix G, (enclosed) of the Center's September 30, 1997 "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers." If the special report is incomplete or contains unacceptable values (e.g., acoustic output greater than approved levels), then the 510(k) clearance may not apply to the production units which as a result may be considered adulterated or misbranded.

The special report should reference the manufacturer's 510(k) number. It should be clearly and prominently marked "ADD-TO-FILE" and should be submitted in duplicate to:

Food and Drug Administration Center for Devices and Radiological Health Document Mail Center (HFZ-401) 9200 Corporate Boulevard Rockville, Maryland 20850

This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.

If you desire specific advice for your device on our labeling requlation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its tollfree number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"

If you have any questions regarding the content of this letter, please contact Rodrigo C. Perez at (301) 594-1212.

Sincerely yours,

Daniel A. Szyman
Daniel G. Schulte, M.D.

aniel G. Schultz, M.D. Captain, USPHS Director, Division of Reproductive, Abdominal and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosures

{2}------------------------------------------------

Device name: SONADA ULTRASOUND SYSTEM

Diagnostic Ultrasound Indications for Use Form

Fill out one form for each ultrasound system and each transducer.

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Mode of Operation
Clinical Application	A	B	M	PWD	CWD	ColorDoppler	AmplitudeDoppler	ColorVelocityImaging	Combined(specify)	Other(specify)
Ophthalmic
Fetal
Abdominal		P
Intraoperative (specify)
Intraoperative Neurological
Pediatric
Small Organ (specify)		P
Neonatal Cephalic
Adult Cephalic
Cardiac
Transesophageal
Transrectal		P
Transvaginal		P
Transurethral
Intravascular
Peripheral Vascular		P		P
Laparoscopic
Musculo-skeletalConventional
Musculo-skeletal Superficial
Other (specify)

N= new indication: P= previously cleared by FDA: E= added under Appendix E Small organ=Breast, Thyroid, Testes Additional Comments:

image =>

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

Jarich A. Sypm

(Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices 42 510(k) Number

3-4

{3}------------------------------------------------

Device Name: CLI 4900 6.5MHz Trans-vaginal (endocavity) probe

Diagnostic Ultrasound Indications for Use Form

Fill out one form for each ultrasound system and each transducer.

İntended Use: Diagnostic utrasound imaging or thuid flow analysis of the human body as follows;

	Mode of Operation
Clinical Application	A	B	M	PWD	CWD	ColorDoppler	AmplitudeDoppler	ColorVelocityImaging	Combined(specify)	Other(specify)
Ophthalmic
Fetal
Abdominal
Intraoperative (specify)
Intraoperative Neurological
Pediatric
Small Organ (specify)
Neonatal Cephalic
Adult Cephalic
Cardiac
Transesophageal
Transrectal
Transvaginal		P
Transurethral
Intravascular
Peripheral Vascular
Laparoscopic
Musculo-skeletalConventional
Musculo-skeletal Superficial
Other (specify)

N= new indication: P= previously cleared by FDA; E= added under Appendix E

Additional Comments:__________________

PLEASE DO NOT WRITE BELOW THIS LINE . CONTINUE ON ANOTHER PAGE WEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

David A. Seymour
(Division Sign-Off)

Division of Reproductive, Abdominal, ENT, and Radiological D 510(k) Number

{4}------------------------------------------------

Device name: CLI 5000 6.5MHz Trans-rectal (endocavity) probe

Diagnostic Ultrasound Indications for Use Form

Fill out one form for each ultrasound system and each transducer.

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows;

	Mode of Operation
Clinical Application	A	B	M	PWD	CWD	ColorDoppler	AmplitudeDoppler	ColorVelocityImaging	Combined(specify)	Other(specify)
Ophthalmic
Fetal
Abdominal
Intraoperative (specify)
Intraoperative Neurological
Pediatric
Small Organ (specify)
Neonatal Cephalic
Adult Cephalic
Cardiac
Transesophageal
Transrectal		P
Transvaginal
Transurethral
Intravascular
Peripheral Vascular
Laparoscopic
Musculo-skeletalConventional
Musculo-skeletal Superficial
Other (specify)

N= new indication; P= previously cleared by FDA; E= added under Appendix E

Additional Comments:__________________________________________________________________________________________________________________________________________________________

(PLEASE DO NOT WRITE BELOW THIS LINE . CONTINUE ON ANOTHER PAGEIF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

David A. Syym
Division Sign-Off

(Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices 510(k) Number

{5}------------------------------------------------

Device name: CLI 6000 12.5MHz Peripheral Vascular probe

Diagnostic Ultrasound Indications for Use Form

Fill out one form for each ultrasound system and each transducer.

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows;

Clinical Application	Mode of Operation
	A	B	M	PWD	CWD	ColorDoppler	AmplitudeDoppler	ColorVelocityImaging	Combined(specify)	Other(specify)
Ophthalmic
Fetal
Abdominal
Intraoperative (specify)
Intraoperative Neurological
Pediatric
Small Organ (specify)		P
Neonatal Cephalic
Adult Cephalic
Cardiac
Transesophageal
Transrectal
Transvaginal
Transurethral
Intravascular
Peripheral Vascular		P		P
Laparoscopic
Musculo-skeletalConventional
Musculo-skeletal Superficial
Other (specify)

N= new indication; P= previously cleared by FDA; E= added under Appendix E Additional Comments:__Small organ = Breast, Thyroid, Testes

PLEASE DO NOT VIRATE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

David Ligon
(Division Sign-Off)

Division of Reproductive, Abdominal, ENT. and Radiological Devic

510(k) Number K993042

{6}------------------------------------------------

Device name: CLI 7900 3.5MHz General Abdominal probe

Diagnostic Ultrasound Indications for Use Form

Fill out one form for each ultrasound system and each transducer.

litended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Mode of Operation
Clinical Application	A	B	M	PWD	CWD	ColorDoppler	AmplitudeDoppler	ColorVelocityImaging	Combined(specify)	Other(specify)
Ophthalmic
Fetal
Abdominal		P
Intraoperative (specify)
Intraoperative Neurological
Pediatric
Small Organ (specify)
Neonatal Cephalic
Adult Cephalic
Cardiac
Transesophageal
Transrectal
Transvaginal
Transurethral
Intravascular
Peripheral Vascular
Laparoscopic
Musculo-skeletalConventional
Musculo-skeletal Superficial
Other (specify)

N= new indication; P= previously cleared by FDA; E= added under Appendix E

Additional Comments:

(PLEASE DO NOT VIRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

David A. Symm

(Division Sign-Off) Division of Reproductive, Abdominal, EN and Radiological Dev 510(k) Number

Regulation Number and Section

§ 892.1650 Image-intensified fluoroscopic x-ray system.

(a)
Identification. An image-intensified fluoroscopic x-ray system is a device intended to visualize anatomical structures by converting a pattern of x-radiation into a visible image through electronic amplification. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). An anthrogram tray or radiology dental tray intended for use with an image-intensified fluoroscopic x-ray system only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9. In addition, when intended as an accessory to the device described in paragraph (a) of this section, the fluoroscopic compression device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.